Core Viewpoint - The China Securities Regulatory Commission (CSRC) emphasizes the importance of prioritizing investor interests in the mutual fund industry, urging firms to shift focus from scale to investor returns, as highlighted by the underperformance of several funds under China Merchants Shekou Fund Management [1][9]. Fund Performance Summary - The fund "Jiaoyin Ruihe Three-Year Holding Mixed Fund," established in March 2022, has seen a cumulative net value decline of 28.86% since inception, significantly underperforming its benchmark by over 20 percentage points [2][9]. - As of May 26, 2025, the fund's net value has dropped by 4.24% in 2025, continuing its trend of underperformance against the benchmark [5]. Fund Composition and Strategy - As of the end of Q1 2025, the fund's total assets were approximately 2.613 billion yuan, with a significant increase in stock holdings, which rose to 93.39% of total assets from 72.49% at the end of Q4 2024 [6]. - The fund manager, He Shuai, has shifted the fund's focus from a heavy allocation in the pharmaceutical sector (over 50% at the end of 2023) to increased investments in the power equipment and banking sectors in 2024 [6]. Top Holdings - The top holdings of the fund as of Q1 2025 include: - Samsung Medical (9.37% of net asset value) - Tencent Holdings (9.10%) - Focus Media (6.98%) - WuXi AppTec (6.22%) - Alibaba (6.05%) - CATL (5.76%) [7][8]. Broader Fund Performance Context - Research indicates that multiple funds under China Merchants Shekou Fund Management have also underperformed their benchmarks by over 20 percentage points over the past three years, raising questions about the investment and risk control strategies employed by the firm [9][12].

每经记者｜叶峰 每经编辑｜肖芮冬 市场早盘震荡调整，创业板指领跌。盘面上热点集中在消费和医药两大方向。在ETF市场，与创新药相关的多只ETF涨幅居前。 | 代码 | 名称 | 现价 涨跌幅 17 | | --- | --- | --- | | 159570.SZ | 港股通创新药ETF | 1.297 2.61% | | 159567.SZ | 港股创新药ETF | 1.287 2.22% | | 513120.SH | 港股创新药ETF | 0.971 2.21% | | 513780.SH | 港股创新药50ETF | 1.241 1.97% | | 520700.SH > 港股创新药ETF基金 | | 1.194 - 1.88% | | 159217.SZ 港股通创新药ETF工银 | | 1.058 1.93% | | 样本代码 | 样本简称 | 所属行业 | 总市值* | | --- | --- | --- | --- | | 01801 | 信达生物 | 矢药卫生 | 885.89 | | 06160 | 百济神州 | 医药卫生 | 2034.42 | | 09926 | 康方生物 | 矢药卫生 | ...

Core Insights - The article discusses the recent notification from Shanghai's health authorities regarding the deepening of public hospital reforms and the promotion of high-level openness in the medical field [1][3] - It emphasizes the encouragement of innovative drug and medical device research, addressing practical challenges faced by companies, and accelerating the drug approval process [3][4] - The notification also highlights the importance of digital transformation in healthcare, including the implementation of artificial intelligence in hospitals [6] Group 1: Public Hospital Reform - The notification mentions the deepening of public hospital reforms with a focus on public welfare, including the adjustment of salary structures in public hospitals [1][3] - It outlines the need for pilot programs in high-quality development hospitals to reform salary distribution systems [1] Group 2: Innovation in Pharmaceuticals and Medical Devices - The notification encourages the research and development of innovative drugs and treatments for rare diseases, while also addressing the high costs associated with clinical trials [3] - It calls for the continuous implementation of policies supporting the innovation of the biopharmaceutical industry and improving the pricing mechanisms for innovative drugs and devices [3][4] Group 3: Digital Transformation in Healthcare - The notification stresses the importance of digital transformation, aiming to implement and promote leading projects in medical artificial intelligence [6] - AI applications in hospitals have significantly improved patient wait times and diagnostic efficiency, showcasing the impact of technology on healthcare services [6]

Group 1: Market Overview - The People's Bank of China conducted a 7-day reverse repo operation of 448 billion yuan at an interest rate of 1.40% on May 27, with 357 billion yuan of reverse repos maturing on the same day [1][5] - A-shares opened slightly lower but showed signs of recovery, with the Shanghai Composite Index fluctuating and turning positive [5][6] - The consumer sector, particularly food and beverage, showed initial strength, while the pharmaceutical sector rebounded [6][12] Group 2: Pharmaceutical Sector - The pharmaceutical and biotechnology sector experienced a partial rebound, with notable stocks such as Longshen Rongfa hitting the daily limit, and Sanofi Guojian rising over 10% [12][13] - Hong Kong pharmaceutical stocks also saw gains, with notable increases in companies like CSPC Pharmaceutical and China Biologic Products [8][14] Group 3: Nuclear Power Sector - The nuclear power sector continued its recent strong performance, with stocks like Shangwei Co. and Rongfa Nuclear Power achieving multiple consecutive gains [9][11] - Recent reports indicate a positive outlook for the controllable nuclear fusion industry, driven by favorable policies and increased financing [11] Group 4: Food and Beverage Sector - The food and beverage sector saw a surge, with stocks like Kuaijishan and Junyao Health achieving significant gains [15][16] - Kuaijishan's market capitalization surpassed that of Guyue Longshan, establishing it as a leading player in the yellow wine industry [15] Group 5: Cultivated Diamond Sector - The cultivated diamond sector experienced a sharp rise, with stocks like Huanghe Xuanfeng and Huifeng Diamond hitting the daily limit [17][18] - Huanghe Xuanfeng announced a partnership to establish a joint venture focused on advanced semiconductor materials, which is expected to enhance the development of high-performance thermal materials [19]

Group 1 - The Hang Seng Index and Hang Seng Tech Index experienced fluctuations, with the Hang Seng Healthcare Index rising by 2.88% and the Hang Seng Healthcare Index ETF (159557) increasing by 2.82% with a turnover rate exceeding 3% [1] - Notable stocks in the healthcare sector included Federated Pharmaceutical, which rose over 8%, along with other companies like CSPC Pharmaceutical and Kangzheng Pharmaceutical also showing gains [1] - The upcoming American Society of Clinical Oncology (ASCO) annual meeting from May 30 to June 3, 2025, is expected to showcase over 70 research results from Chinese pharmaceutical companies, highlighting innovative drug candidates with potential for best-in-class status [1] Group 2 - Citic Securities indicated a clear trend of performance and valuation recovery in the healthcare industry, with a focus on innovation-driven strategies and internationalization, as well as reforms in outpatient marketing models for the second half of the year [2] - The A-share pharmaceutical sector and Hong Kong's innovative drug sector are currently at five-year low positions, with public fund holdings in the pharmaceutical industry reaching their lowest point since Q2 2020 in Q4 2024, but showing signs of recovery in Q1 2025 [2] - The global pharmaceutical investment and financing scale has shifted from a downward trend to a low-level oscillation upwards, with many growth-oriented pharmaceutical companies currently having PEG levels below 1, indicating potential for performance and valuation improvements [2] Group 3 - China’s innovative drug licensing out (Lisence out) total amount is projected to exceed $50 billion in 2024, reaching $51.9 billion, a year-on-year increase of 27.4%, accounting for 30% of the global total in similar transactions [3] - The record licensing amount for SSGJ-707 is expected to accelerate the trend of Chinese pharmaceutical companies expanding internationally, with a noticeable increase in the number and value of licensing out agreements in recent years [3]

Core Viewpoint - President Donald Trump has abandoned the threat of imposing a 50% tariff on EU imports, allowing more time for negotiations between Washington and the 27 EU countries [1] Group 1: EU Exports to the US - In 2024, the US is the largest export partner for the EU, accounting for 20.6% of EU exports [1] - The top three countries exporting from the EU to the US are Germany (€161 billion, approximately $182.6 billion), Ireland (€72 billion), and Italy (€65 billion) [3] - The main products exported from the EU to the US include pharmaceuticals (€120 billion), automobiles (€40 billion), and aircraft and related equipment [3][4] Group 2: Pharmaceuticals - In 2024, the EU exported approximately €120 billion worth of pharmaceutical products to the US [3] - Major pharmaceutical companies in the EU include Novo Nordisk, Bayer, Roche, and Novartis [3] Group 3: Automobiles - The EU exports about 750,000 cars to the US annually, valued at approximately €40 billion, representing 14% of the EU's total automotive production [4] - Major car manufacturers affected by US trade policies include Mercedes-Benz, Stellantis, and Volvo [4] - Volkswagen is significantly impacted by tariffs due to its high-end Audi brand not being produced in the US, but plans to announce production of some best-selling models in the US [4] Group 4: Aircraft and Equipment - Airbus is the second-largest exporter in France, with about 12% of its aircraft sold to the US, some of which are assembled locally [5] - CFM International, a major supplier for Airbus and Boeing, is co-owned by Safran and GE Aviation [5] Group 5: Alcohol and Beverages - In 2024, the EU exported approximately €9 billion worth of alcoholic beverages to the US, with European spirits valued at €2.9 billion [9] - Major European beverage producers include Heineken, Diageo, and Carlsberg [9] Group 6: Cosmetics - The EU exported cosmetics, perfumes, and personal care products worth approximately $10.47 billion to the US in 2024 [10] - French company L'Oréal exports about €2.5 billion worth of cosmetics to the US annually [11] Group 7: Luxury Goods - About one-quarter of products from major luxury goods groups are aimed at US consumers, with smaller brands having varying market shares [12] - The French luxury goods industry is the largest globally, employing over 600,000 people [13] - The luxury goods sector is significantly affected by US tariffs, as companies have limited ability to shift production to the US [14]

Market Overview - Global stock markets experienced a correction last week, with a risk preference retreating from high levels. The MSCI Global Index fell by 1.9%, with developed markets down by 2.1% and emerging markets down by 0.5% [3][10] - The Hang Seng Index showed the best performance among emerging markets, increasing by 1.1%, while the Korean Composite Index was the weakest, declining by 1.3% [3][10] Sector Performance - In the US market, defensive sectors such as utilities and consumer staples performed well, while technology sectors faced adjustments. The S&P 500 saw a decline of 2.6% [10] - In the European market, utilities and communication services led with gains of 2.6% and 2.3%, while consumer discretionary and energy sectors lagged behind [10] - The Hong Kong market saw significant gains in the materials and healthcare sectors, with increases of 6.1% and 5.6%, respectively [10] Valuation Trends - Developed markets' overall valuation decreased, with the latest PE and PB ratios at 21.9x and 3.5x, respectively, placing them at the 86% and 97% percentile levels since 2010 [21] - Emerging markets' valuations improved, with PE and PB ratios at 15x and 1.9x, respectively, at the 72% and 85% percentile levels since 2010 [22] Earnings Expectations - Earnings expectations for global markets were mostly revised downwards, with Hong Kong showing a notable upward revision. The Hang Seng Index's 2025 EPS forecast was adjusted from 2214 to 2222 [27] - The S&P 500's 2025 EPS forecast was revised down from 264 to 263, with the consumer discretionary sector seeing the largest upward revision of +0.2% [27][28] Liquidity Conditions - Global liquidity conditions tightened marginally last week, with macro liquidity indicators showing a mixed trend across regions. The US and China saw interest rates decline, while European rates slightly increased [30] - The tightening of liquidity was reflected in the increase of long-term bond yields in major countries, with the UK, Japan, and the US seeing the largest increases [30] Economic Outlook - The economic outlook showed divergence, with the US economy experiencing a marginal decline in sentiment, as indicated by a drop in the manufacturing PMI to 48.7% [35] - In contrast, the European economy maintained stability, with the Eurozone manufacturing PMI at 49% and service PMI at 50.1%, indicating continued expansion [43]

Group 1 - The core point of the article highlights the performance and holdings of the Guangfa Healthcare Stock A fund, which has a recent net value of 1.7952 yuan, reflecting a decline of 1.28% [1] - The fund's performance over the past month shows a return of 1.70%, ranking 419 out of 940 in its category; over the past six months, it has achieved a return of 8.97%, ranking 232 out of 914; and since the beginning of the year, it has returned 11.06%, ranking 118 out of 926 [1] - The top ten holdings of the Guangfa Healthcare Stock A fund account for a total of 48.15%, with significant positions in companies such as Zai Lab (10.52%), Kelun Pharmaceutical (8.39%), and others [1] Group 2 - Guangfa Healthcare Stock A fund was established on August 10, 2017, and as of March 31, 2025, it has a total scale of 5.237 billion yuan, managed by fund manager Wu Xingwu [1] - Wu Xingwu has extensive experience in the investment management field, having held various positions in Guangfa Fund Management and previously at Morgan Stanley Huaxin Fund Management [2]

Group 1 - The core viewpoint of the article highlights the recent market trends, indicating a mixed performance with a decline in the overall A-share market by 0.63%, while certain sectors like precious metals and pharmaceuticals showed strength due to specific catalysts [2][15] - The small-cap stocks exhibit resilience despite adjustments, with a significant trading volume in the small-cap index, indicating concentrated capital allocation in this segment [16] - The "new consumption" trend is characterized by individual company innovations rather than a broad market shift, emphasizing the importance of specific stocks over general sector trends [17] Group 2 - The pharmaceutical sector continues to benefit from favorable developments, including significant licensing agreements and upcoming clinical presentations, which are expected to drive further interest and investment [18] - The dividend sector is experiencing a temporary pause in differentiation, with financial institutions increasingly focusing on stable dividend-paying assets amid changing market conditions [19] - The public fund market is adapting to new regulations, with 26 floating management fee funds approved shortly after the release of a new development action plan [20][21] Group 3 - The performance of various active equity fund indices shows mixed results, with the medical and consumer sectors performing well, while technology and high-end manufacturing sectors faced declines [24][25] - The active stock fund selection process emphasizes a balanced approach, considering both value and growth styles to optimize returns [26][28][32] - The medical and consumer fund indices have shown significant excess returns since their inception, indicating strong performance in these sectors [9][10][18]

金十数据5月26日讯，恒指今早低开低走，午后维持水下震荡态势持续下探，最低见23234.27点。恒生 科技指数午后一度跌逾2%。截至收盘，恒指收跌1.35%，报23282.33点，科指收跌1.7%，报5157.65点， 恒指大市成交额达2235.2亿港元（上一交易日为2036.71亿港元）。盘面上，美股核电板块大涨带动港股 核电板块表现突出，科网股走势分化，汽车股领跌大盘，医药股回调走弱。个股方面，中核国际 (02302.HK)收涨129.78%，同程旅行(00780.HK)收涨4.39%，名创优品(09896.HK)绩后收跌18.22%，比亚 迪股份(01211.HK)收跌8.6%，宁德时代(03750.HK)收跌2.61%，小米集团(01810.HK)收跌3.21%，恒瑞医 药(01276.HK)收跌2.63%。 港股收评：恒指水下震荡收跌1.35% 汽车整车板块表现疲软 ...